Orion OYJ Q4 2024 Earnings Report

Orion OYJ EPS Results

• Actual EPS: $0.28
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Orion OYJ Revenue Results

• Actual Revenue: $463.41 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Orion OYJ Announcement Details

• Quarter: Q4 2024
• Date: 2/25/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Orion OYJ (OTCMKTS:ORINY) is a Finland-based pharmaceutical company that develops, manufactures and markets human and veterinary medicines. Its portfolio includes proprietary prescription treatments, generic medicines, consumer health products and pharmaceutical active ingredients.

The company focuses its research and commercial activities on areas including central nervous system disorders, oncology, respiratory diseases, veterinary medicine and pain management. Orion also works with international pharmaceutical companies through licensing, development and commercialization partnerships.

Founded in 1917, Orion is headquartered in Espoo, Finland, and serves customers through operations and partnerships in Finland, Europe and other international markets. Its products are sold in numerous countries, with the company maintaining a particularly strong presence in the Nordic region.

Orion is led by President and Chief Executive Officer Liisa Hurme. The company is listed on Nasdaq Helsinki, while its shares also trade in the U.S. over-the-counter market under the symbol ORINY.